amphetamine has been researched along with Basal Ganglia Diseases in 16 studies
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The enhancement of immobility in a forced swimming test of mice induced by repeated treatment with phencyclidine and amphetamine swimming "normalization" test of mice were used as animal models of negative and positive symptoms of schizophrenia, respectively." | 3.70 | Atypical antipsychotic effects of quetiapine fumarate in animal models. ( Dai, J; Guan, HJ; Zhu, XZ, 2000) |
| " Tremors induced by chemical agents (nicotine, zinc and tremorine) were markedly inhibited by HA-966." | 3.65 | 1-Hydroxy-3-amino-pyrrolidone-2(HA-966): a new GABA-like compound, with potential use in extrapyramidal diseases. ( Bonta, IL; De Vos, CJ; Grijsen, H; Hillen, FC; Noach, EL; Sim, AW, 1971) |
| "Methamphetamine (METH) is a psychostimulant that induces excessive release of dopamine (DA) in the striatum." | 1.33 | Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors. ( Angulo, JA; Xu, W; Zhu, JP, 2005) |
| " A long-term use of the preparation leads to development of habituation, while its cessation--to symptoms similar to withdrawal." | 1.26 | [Influence of extrapyramidal disorders induced by haloperidol on phenamine stereotypy and the effects of schizophrenic patients' serum (experimental study)]. ( Bobritskaia, ZM; Gorbatko, LG; Litvinova, NM; Stoliarov, GV, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (68.75) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andersen, MB | 1 |
| Fuxe, K | 1 |
| Werge, T | 1 |
| Gerlach, J | 2 |
| Xu, W | 1 |
| Zhu, JP | 1 |
| Angulo, JA | 1 |
| Migler, BM | 1 |
| Warawa, EJ | 1 |
| Malick, JB | 1 |
| Peacock, L | 1 |
| Hansen, L | 1 |
| Mørkeberg, F | 1 |
| Guan, HJ | 1 |
| Dai, J | 1 |
| Zhu, XZ | 1 |
| Kudrin, AN | 1 |
| Davydova, ON | 1 |
| Krendal', FP | 1 |
| Bobritskaia, ZM | 1 |
| Gorbatko, LG | 1 |
| Litvinova, NM | 1 |
| Stoliarov, GV | 1 |
| Crossman, AR | 1 |
| Sambrook, MA | 1 |
| Gergies, SW | 1 |
| Slater, P | 1 |
| Brundin, P | 1 |
| Isacson, O | 1 |
| Gage, FH | 1 |
| Prochiantz, A | 1 |
| Björklund, A | 1 |
| Greenblatt, DJ | 1 |
| Shader, RI | 1 |
| Calne, DB | 1 |
| Reid, JL | 1 |
| Hornykiewicz, O | 1 |
| Rubovits, R | 1 |
| Klawans, HL | 1 |
| Bonta, IL | 1 |
| De Vos, CJ | 1 |
| Grijsen, H | 1 |
| Hillen, FC | 1 |
| Noach, EL | 1 |
| Sim, AW | 1 |
| Arnold, OH | 1 |
| Collard, J | 1 |
| Deniker, P | 1 |
| Ginestet, D | 1 |
| Hippius, H | 1 |
| Itil, TM | 1 |
| Labhardt, F | 1 |
| Leeds, AA | 1 |
| Montanini, R | 1 |
| Morozov, G | 1 |
| Simon, P | 1 |
| Villeneuve, A | 1 |
| Julou, L | 1 |
3 reviews available for amphetamine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Rational use of psychotropic drugs. III. Major tranquilizers.
Topics: Adrenergic alpha-Antagonists; Amphetamine; Antiemetics; Antipsychotic Agents; Basal Ganglia Diseases | 1974 |
Antiparkinsonian drugs: pharmacological and therapeutic aspects.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Amantadine; Amphetamine; Antiparkinson Agents; Apomorphi | 1972 |
Pharmacology and pathophysiology of dopaminergic neurons.
Topics: Amphetamine; Animals; Basal Ganglia Diseases; Brain; Butyrophenones; Cats; Cattle; Dopamine; Ganglia | 1971 |
13 other studies available for amphetamine and Basal Ganglia Diseases
| Article | Year |
|---|---|
The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys.
Topics: Adenosine; Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Arousal; Basal Ganglia Diseases; | 2002 |
Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors.
Topics: Amphetamine; Amphetamine-Related Disorders; Animals; Apoptosis; Basal Ganglia Diseases; Corpus Stria | 2005 |
Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Basal Ganglia Diseases; | 1993 |
Chronic dopamine D1, dopamine D2 and combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys: antiamphetamine effects and extrapyramidal side effects.
Topics: Amphetamine; Animals; Arousal; Basal Ganglia Diseases; Benzazepines; Benzofurans; Cebus; Dopamine Ag | 1999 |
Atypical antipsychotic effects of quetiapine fumarate in animal models.
Topics: Amphetamine; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Disease Models, Anima | 2000 |
[Pharmacologic incompatibility of neuroleptics and tranquilizers with other medicines].
Topics: Amphetamine; Animals; Anti-Anxiety Agents; Anti-Arrhythmia Agents; Anticonvulsants; Antipsychotic Ag | 1977 |
[Influence of extrapyramidal disorders induced by haloperidol on phenamine stereotypy and the effects of schizophrenic patients' serum (experimental study)].
Topics: Amphetamine; Animals; Basal Ganglia Diseases; Behavior; Behavior, Animal; Haloperidol; Humans; Immun | 1977 |
The neurological basis of motor asymmetry following unilateral 6-hydroxydopamine brain lesions in the rat: the effect of motor decortication.
Topics: Amphetamine; Animals; Apomorphine; Basal Ganglia; Basal Ganglia Diseases; Brain Mapping; Cerebral De | 1977 |
The rotating 6-hydroxydopamine-lesioned mouse as a model for assessing functional effects of neuronal grafting.
Topics: Amphetamine; Animals; Basal Ganglia Diseases; Corpus Striatum; Disease Models, Animal; Dopamine; Hyd | 1986 |
Implications of amphetamine-induced stereotyped behavior as a model for tardive dyskinesias.
Topics: Amphetamine; Animals; Basal Ganglia; Basal Ganglia Diseases; Brain Chemistry; Caudate Nucleus; Chlor | 1972 |
1-Hydroxy-3-amino-pyrrolidone-2(HA-966): a new GABA-like compound, with potential use in extrapyramidal diseases.
Topics: Acoustic Stimulation; Amines; Amphetamine; Animals; Basal Ganglia Diseases; Behavior, Animal; Brain | 1971 |
Definition and classification of neuroleptics.
Topics: Amphetamine; Animals; Apomorphine; Autonomic Nervous System; Basal Ganglia Diseases; Behavior; Catal | 1970 |
On the interaction between neuroleptics and antiparkinson drugs.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Behavior, Animal; C | 1970 |